Johnson & Johnson says its single-dose vaccine was 66 percent effective in preventing Covid-19 in a large global trial against multiple variants.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe Covid-19 varied from 72 percent in the United States, to 66 percent in Latin America and just 57 percent in South Africa, from where a worrying variant has spread.
The data showed that the vaccine’s effect on the South Africa variant was diminished compared to the unaltered virus, but infectious disease and public health experts said it could still help contain the virus spread and prevent deaths.
Midstage trial data from Novavax yesterday also documented lower effectiveness in South Africa.
Rival shots from Pfizer/BioNTech and Moderna were both about 95 percent effective in preventing symptomatic illness in pivotal trials when given in two doses.
Those trials were conducted mainly in the United States and before the emergence of new variants. These mean that the world is racing against time and with limited supplies to vaccinate as many people as possible, and quickly, to prevent virus surges.
Covid-19 is rising in 37 countries and infections have surpassed 101 million globally.
Top US infectious disease specialist Anthony Fauci said the world needed to vaccinate quickly to try to get ahead of these changes in the virus.
“It’s really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve,” Fauci said.
J&J’s main goal was the prevention of moderate to severe Covid-19, and the vaccine was 85 percent effective in stopping severe disease and preventing hospitalisation across all geographies and against multiple variants 28 days after immunisation.
That “will potentially protect hundreds of millions of people from serious and fatal outcomes of Covid-19,” Paul Stoffels, J&J’s chief scientific officer, said.
J&J shares were down 4 percent at $162.7 at 1700 GMT, with some Wall Street analysts saying its vaccine’s effectiveness was below those of rivals. Moderna’s stock gained 8 percent to $172.80.
J&J plans to seek emergency use authorisation from the US Food and Drug Administration next week and will soon follow up with the European Union and the rest of the world.
It has said it plans to deliver 1 billion doses of the vaccine, which it will make in the United States, Europe, South Africa and India, in 2021.
Public health officials are counting on it to increase much-needed supply and simplify immunisation in the United States, which has a deal to buy 100 million doses of J&J’s vaccine and an option for an additional 200 million.
J&J said the vaccine would be ready immediately upon emergency approval, but Stoffels declined to say how many doses.
“The key is not only overall efficacy but specifically efficacy against severe disease, hospitalisation, and death,” said Walid Gellad, a health policy associate professor at the University of Pittsburgh.
J&J’s vaccine uses a common cold virus to introduce coronavirus proteins into cells and trigger an immune response, whereas the Pfizer/BioNTech and Moderna vaccines employ a new technology called messenger RNA.
Unlike these vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world where transportation and cold storage present problems.
“Most countries are still desperate to get their hands on doses, regardless of whether or not the vaccine is considered highly effective. Moderately effective will do just fine for now,” Michael Breen, director of infectious diseases and ophthalmology at research firm GlobalData, said.
Several studies have emerged this month showing that a South African variant has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.
“What we are learning is there is different efficacy in different parts of the world,” Stoffels told Reuters.
In a sub-study of 6000 volunteers in South Africa, Stoffels said, the J&J vaccine was 89 percent effective at preventing severe disease. In the South Africa portion of the trial, 95 percent of cases were infections with the South African variant.
“I am overwhelmed by the fact that this vaccine protected against severe disease even in South Africa,” said Glenda Gray, the joint lead investigator of the South African vaccine trial.
In the J&J trial, which was conducted in eight countries, 44 percent of participants were from the United States, 41 percent from Central and South America and 15 percent from South Africa. Just more than a third of the volunteers were over 60.